Chief of Cardiovascular Medicine’s Analysis Published in JAMA

Dr. Mukherjee

The recently published JAMA article “Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage: A Meta-Analysis” authored by Debabrata Mukherjee, M.D., professor and chairman of the TTUHSC at El Paso Department of Internal Medicine and chief of cardiovascular medicine is the first analysis of thrombolysis done on patients with pulmonary embolisms that has sufficient statistical power to detect associations with a meaningful mortality reduction with special attention paid to the subpopulation of patients presenting with intermediate-risk pulmonary embolisms. “Several small trials have previously evaluated the role of thrombolytics in pulmonary embolism for patients without definitive results due to lack of adequate power. Therefore, we performed a meta-analysis of all randomized trials of thrombolytic therapy in pulmonary embolism,” said Dr. Mukherjee.  “We aimed to ascertain associations of thrombolytic therapy with bleeding risk and potential mortality benefits. This study demonstrates lower overall associated mortality with thrombolytic use in pulmonary embolism. Furthermore, results also suggest a potential mortality benefit with thrombolytic therapy in patients with hemodynamically stable pulmonary embolism with right ventricular dysfunction or in intermediate-risk pulmonary embolism. However, the optimism regarding this clinical advantage must be tempered by the finding of significantly increased risk of major bleeding and intracranial hemorrhage associated with thrombolytic therapy, particularly for patients older than 65 years.”  Read summary at:


Additional articles featuring Dr. Mukherjee’s work may be accessed through the following links: